Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Acquired by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lifted its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 13.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 35,894 shares of the specialty pharmaceutical company’s stock after acquiring an additional 4,332 shares during the period. Hennion & Walsh Asset Management Inc. owned 0.06% of Jazz Pharmaceuticals worth $4,420,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Itau Unibanco Holding S.A. acquired a new position in shares of Jazz Pharmaceuticals in the second quarter valued at about $29,000. EverSource Wealth Advisors LLC increased its holdings in Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 97 shares during the period. GAMMA Investing LLC increased its holdings in Jazz Pharmaceuticals by 41.3% in the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 121 shares during the period. Venturi Wealth Management LLC raised its position in Jazz Pharmaceuticals by 577.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after buying an additional 704 shares during the last quarter. Finally, Versant Capital Management Inc lifted its stake in Jazz Pharmaceuticals by 56.7% during the 4th quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock valued at $119,000 after acquiring an additional 350 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Up 0.2 %

NASDAQ:JAZZ opened at $123.24 on Thursday. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $134.17. The stock’s fifty day moving average is $122.76 and its two-hundred day moving average is $114.44. The stock has a market capitalization of $7.45 billion, a price-to-earnings ratio of 17.36, a price-to-earnings-growth ratio of 0.88 and a beta of 0.56. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Insider Buying and Selling

In other news, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the transaction, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the sale, the chief executive officer now owns 425,525 shares in the company, valued at $52,522,550.75. The trade was a 0.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 8,253 shares of company stock valued at $1,001,434. Corporate insiders own 4.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on JAZZ. TD Cowen lowered their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $140.00 to $175.00 in a report on Thursday, December 12th. Piper Sandler restated an “overweight” rating and set a $163.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Royal Bank of Canada restated an “outperform” rating and issued a $179.00 target price on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $177.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.